To include your compound in the COVID-19 Resource Center, submit it here.

Genome toolbox

How Inscripta complements genome reading, writing plays in investors’ portfolios

The syndicate behind Inscripta Inc.’s $55.5 million series C round includes investors well-versed in genome reading and writing that are making a foray into genome editing.

New investor Mérieux Développement and existing investor Paladin Capital led the round, which

Read the full 395 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE